Title : Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.

Pub. Date : 2001 Mar 1

PMID : 11230472






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The purpose of this study was to determine whether posttreatment declines in PSA were associated with clinical measures of improvement in a randomized phase III trial of suramin plus hydrocortisone versus placebo plus hydrocortisone. Suramin kallikrein related peptidase 3 Homo sapiens
2 RESULTS: A decline in PSA of > or = 50% lasting > or = 28 days was significantly associated with a prolonged median overall survival, OPFS, and TTPP, both in the entire group and the suramin plus hydrocortisone group at all three landmarks in both univariate and multivariate analysis. Suramin kallikrein related peptidase 3 Homo sapiens
3 CONCLUSION: In this prospective, randomized trial of suramin plus hydrocortisone versus placebo plus hydrocortisone, a posttherapy decline in PSA of > or = 50%, lasting 28 days, was associated with prolonged median overall survival, improved median progression-free survival, and median TTPP. Suramin kallikrein related peptidase 3 Homo sapiens